Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement with Sarepta

Summit Therapeutics plc
Posted on: 04 Oct 16

Summit Therapeutics plc

("Summit" or the "Company")

SUMMIT TO HOST CONFERENCE CALL TO DISCUSS EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT WITH SAREPTA THERAPEUTICS FOR EUROPEAN RIGHTS TO SUMMIT'S UTROPHIN MODULATOR PIPELINE FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Oxford, UK, 4 October 2016 ­ - Summit Therapeutics plc (NASDAQ:SMMT, AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, announces that in conjunction with today's announcement on an exclusive license and collaboration agreement with Sarepta Therapeutics for European rights to Summit's utrophin modulator pipeline for the treatment of DMD, Summit will be holding a conference call at 1:00pm BST / 8:00am EDT.

To participate in the conference call, please dial +44(0)20 3427 1918 (UK and international participants) or +1 646 254 3365 (US local number) and use the conference confirmation code 6907795. Investors may also access a live audio webcast of the call via the investors section of the Company's website www.summitplc.com. A replay of the webcast will be available shortly after the presentation finishes.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)

 
 

Tel: +44 (0)1235 443 951
 +1 617 225 4455
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson

 
 

 Tel: +44 (0)20 7148 7900
N+1 Singer
(Broker)
Aubrey Powell / Jen Boorer 

 
 

Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications
(US media contact)
Chris Erdman / Karen Sharma

 

Tel: +1 781 235 3060
cerdman@macbiocom.com   ksharma@macbiocom.com
Consilium Strategic Communications
(Financial public relations, UK)
Mary-Jane Elliott / Sue Stuart / 
Jessica Hodgson / Lindsey Neville


Tel: +44 (0)20 3709 5700
summit@consilium-comms.com

-END-



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Summit Therapeutics plc via GlobeNewswire
HUG#2046442
GlobeNewswire
globenewswire.com

Last updated on: 05/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.